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LIVER PRESERVATION WITH LIDOFLAZINE AND THE UNIVERSITY OF WISCONSIN SOLUTION: 
A DOSE-FINDING STUDY) 
Over the last decade, two major advances have made liver 
transplantation a widely applied and successful treatment of 
endstage liver disease. First, improvements in immunosuppres-
sion made possible by cyclosporine (1) and the recently intro-
duced, even more powerful, immunosuppressant FK 506 (2) 
have reduced graft loss due to rejection. Second, a breakthrough 
in preservation of the liver for transplantation was recently 
achieved by the University of Wisconsin cold storage solution 
(UW)* (3). Thus, it is now possible to safely preserve a human 
liver for up to 24 hr (4). This has simplified the logistics in 
liver transplantation and also contributed to an improved qual-
ity of the organs that are transplanted. In spite of this, there is 
still a need for methods to further improve both the duration 
and the quality of preservation. 
Numerous studies have demonstrated that cell and organ 
injury from ischemia can be reduced by avoiding the occurrence 
of elevated intracellular Ca2+ levels, e.g., by the use of Ca2+ 
antagonists (5-8). Previously, a protective effect was found 
when lidoflazine, a Ca2+ antagonist, was added to UW solution 
for preservation of the rat kidney (9). In the present study, we 
have investigated the effect of lidoflazine on liver preservation 
with UW solution, using the isolated perfused rat liver model. 
The experiments were performed on male Lewis rats, weigh-
ing 240-340 g (Harlan, Indianapolis, IN). The animals had free 
access to standard pellet diet and tap water, and were not fasted 
before surgery. Anesthesia was with inhalational methoxyflu-
rane (Metofane; Pitman-Moore, Inc., Washington Crossing, 
NJ). 
Heparin, 300 IU, was given i.v. 10 min before harvesting. 
Ligatures were placed around the inferior vena cava, cranially 
to the renal vein and artery, and around the portal vein. For 
bile collection, polyethylene tubing (PE-lO, I.D. 0.28 mm, O.D. 
O.Sl mm; Clay Adams, Parsippany, NJ) was inserted into the 
bile duct. Immediately after cannulation of the portal vein with 
a IS-gauge catheter (Critikon, Inc., Tampa, FL), this catheter 
was connected to an extension set and a SO-ml syringe (Abbott 
Laboratories, North Chicago, IL) filled with ice-cold preserva-
tion solution and immediately flushed in situ. The vena cava 
was transected distally to the ligature. Using this procedure, 
the warm ischemia time was always shorter than 20 sec. The 
liver was flushed with 30 ml at a hydrostatic pressure of 15-20 
cm H20. During flushing, a 14-gauge catheter (Deseret Medical 
Inc., Sandy, UT) was inserted into the infrahepatic vena cava; 
the suprahepatic vena cava was transsected and the hepatec-
tomy was completed. Each liver was weighed and stored in 100 
ml of preservation solution for 72 hr, kept surrounded by ice. 
The perfusions were performed in a thermostatically con-
trolled Plexiglass cabinet (65x32x60 cm; Fischer Scientific, 
Pittsburgh, PAl. Each liver was continuously perfused through 
the portal vein with 200 ml of recirculating buffer at 38°C for 
90 min, using a Masterflex pump controller (Cole-Parmer In-
strument, Chicago, IL) calibrated to maintain a flow rate of 3.5 
ml/min/g. The perfusate was oxygenated while passing through 
1 This work was supported by grants from the Department of Veteran 
Affairs, the Swedish-American Foundation, and by Project Grant 
DK29961 from the National Institutes of Health. 
* Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate 
aminotransferase; LDH, lactate dehydrogenase; PNP, purine nucleo-
tide phosphorylase; UW, University of Wisconsin solution. 
oxygen-permeable tubing (T57111115-6, I.D. 1.5 mm; American 
Scientist, Warrendale, P A) inside a plastic container with a 
95% O2 and 5% CO2 mixture at a flow rate of S ml/min, giving 
an oxygen tension of 480-550 mmHg on the arterial side of the 
system. Air bubbles were avoided by connecting a disposable 
Nylon filter (blood set 64; Abbott Laboratories) in line between 
the oxygenator and the inflow. The portal vein pressure was 
continuously monitored with an in-line manometer (Abbott 
Laboratories) . 
Krebs-Hanseleit bicarbonate solution containing 2% albu-
min (Sigma, St. Louis, MO) and 5 mM glucose (Abbott Labo-
ratories) was used as the perfusate. The initial pH was adjusted 
to 7.38-7.42, but was not further adjusted during the perfusion, 
since the pH had earlier been found to decrease by not more 
than 0.10-0.15 (unpublished data). The preserved livers were 
weighed, then flushed with 3 ml of lactated Ringer's solution 
(Baxter Healthcare Corp., Deerfield, IL) at room temperature 
through the portal vein and immediately connected to the 
perfusion apparatus. The bile was collected in preweighed test 
tubes placed outside the cabinet to avoid dilution of the bile by 
condensed water, and the amount of bile produced was estab-
lished by weighing the bile samples, assuming the bile density 
to be equal to water. Perfusate samples were taken every 30 
min for measurement of aspartate aminotransferase (ASA T), 
alanine aminotransferase (ALAT), lactate dehydrogenase 
. (LDH), and purine nucleotide phosphorylase (PNP). Perfusate 
samples were also taken for immediate measurements of pH, 
p02, and pC02 from the inflow as well as the outflow using a 
pH-blood gas meter (ABL 2-acid-base laboratory; Radiometer, 
Copenhagen, Denmark). After the perfusion, the liver was again 
weighed and the bile volume was measured. The release of the 
hepatocellular enzymes was determined with colorimetric 
methods (Sigma), using a Technicon RA-500 analyzer. Levels 
of PNP in the perfusate were measured, using the method of 
Hoffee et a1. (10). 
Six different doses of lidoflazine (4-[4,4-bis(4-fluoro-
phenyl) butyl]-N -(2,S-dimethylphenyl) -l-piperazineacetamide; 
Kabi Pharmacia, La Jolla, CAl were dissolved in UW solution 
(DuPont, Wilmington, DE) on the day of the harvest. The 
doses tested were 0.078 mg/L (l.SXlO-7 M), 0.312 mg/L 
(6.3XlO-7 M), 1.25 mg/L (2.5XlO-6 M), 5 mg/L (1.0XlO-o M), 
20 mg/L (4.1 X 10-5 M), and 80 mg/L (1.6xlO-4 M). The same 
solution was used for both flush-out and cold storage. In a 
control group, plain UW solution was used. Six experiments 
were performed in each group. 
Results were calculated as mean ± SD. Statistical compari-
sons were performed using the Wilcoxon rank sum test. A P-
value less than 0.05 was considered statistically significant. 
As seen in Figure 1, in which the amount of ASAT released 
into the perfusate is presented in control livers with 0, 24, 48, 
and 72 hr of cold ischemia time, a clear-cut difference between 
the 48-hr and 72-hr preserved livers was seen. Since a certain 
amount of damage is required in a model, in which quantifica-
tion of improved preservation is a major goal, 72 hr was chosen 
for the experiments. The other enzymes tested (ALAT, LDH, 
and PNP) behaved in a similar fashion in these control exper-
iments, and the differences reached the same levels of signifi-
cance (data not shown). 
The levels of enzymes in the 72-hr preserved livers, released 
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FIGURE 1. AS AT levels after 90 min of reperfusion, after 0, 24, 48, 
and 72 hr of cold storage in plain UW solution. The differences between 
the 72-hr group and the other groups were all significant (P<O.OOl). 
into the perfusate during reperfusion, are given in Figure 2. For 
simplicity, only the 90-min values are presented. The 30-min 
and 60-min values were proportionally lower than the corre-
sponding 90-min values, and the statistical comparisons in the 
30- and 60-min values reached the same levels of significance 
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FIGURE 2. Enzyme levels in the perfusate 90 min after reperfusion. 
A. ASAT: The levels of statistical 8ignificsnce for the different doses 
of lidotlazine (mg/L) compared with controls were: P<O.Ol for 0.078, 
0.312, and 5; P<0.05 for 1.25; and NS for 20 and BO. B. ALAT: The 
levels of statistical significance for the different doses of lidotlazine 
(mg/L) compared with controls were: P<O.O! for 0.312; P<O.05 for 5 
and 1.25; and NS for 0.078, 1.25, 20, andSO. C:LDH: The levels of 
as these. The four lowest doses of lidoflazine (0.078-5 mg/L) 
were all effective in preventing enzyme release, as compared 
with when plain UW was used. The ASAT, LDH, and PNP 
9O-min values from these groups were all significantly lower 
than the values from the control group. When comparing the 
ALAT values, the 0.312- and 5-mg/L groups had significantly 
lower values. However, the two highest doses (20 and 80 mg/L, 
groups 5 and 6) were not significantly different in UW for any 
enzyme tested. 
In contrast to our experiences from the isolated perfused 
rabbit liver (11-15), measurement of the bile production was 
technically difficult, since biliary sludge would sometimes ob-
struct the thin catheter in the groups of preserved livers, or 
kinking of the catheter would occur, which was not easily 
detected because of the low volumes produced. Therefore, a 
number of experiments in each group had to be excluded. and 
no valid conclusions could be drawn from this parameter only. 
Instead, the results of the enzyme analyses were regarded as 
more reliable indicators of liver cell injury after preservation 
in this rat model. However, as seen in previous studies (11,15)' 
bile production in control livers gradually decreased with in-
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statistical significance for the different doses of lidotlazine (mg/L) 
compared with controls were: P<O.OI for 0.078, 0.312. and 5; P<0.05 
for 1.25; and NS for 20 and BO. D. PNP: The levels of statistical 
significance for the different doses of lidotlazine (mg/L) compared with 
controls were: P<O.OI for 0.078 and 5; P<0.05 for 0.312 and 1.25; and 
NS for 20-and SO. 
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creasing ischemia time (1.l±3.4 [n=6], O.59±O.22 [n=5), 0.27± 
0.15 [n=3], and 0.19±O.06 [n=4] ml/90 min in the 0-, 24- 48-, 
and 72-hr preserved livers, respectively. Bile production after 
72 hr appeared to improve with addition of at least moderate 
to higher doses of lidoflazine (0.17±0.06, [n=4], 0.21±0.04 
[n=3), 0.25±0.09 [n=4J, 0.25±0.06 [n=3), 0.25±0.08 [n=5), and 
0.25±0.05 [n=4] ml/90 min for the 0.078-, 0.312-, 1.25-, 5-, 
20-, and SO mg/L groups, respectively, but due to the low 
number of evaluable experiments, no statistically significant 
differences could be calculated. The bile in 72-hr preserved 
livers was pale as compared with fresh or 24-hr preserved livers. 
The portal vein pressure was 11.0±2.2 cm H20 for all groups 
without any significant differences. One experiment in the 1.25-
mg/L group was excluded because of air embolism. There was 
no difference in liver weights after flush-out between the 
groups. During preservation, all livers decreased in weight, 
which is a well-known phenomenon with UW (13). The addi-
tion of lidoflazine did not affect the liver weight during cold 
storage. 
As indicated by the enzyme data, lidoflazine significantly 
improved the capacity of UW to preserve rat livers. Since the 
concentrations of the hepatocellular enzymes (ASAT, ALAT, 
and LDH) and the endothelial enzyme (PNP) were lower for 
the four lowest doses of lidoflazine tested, compared with UW 
alone, the present data suggest that lidoflazine improves the 
preservation of hepatocytes as well as liver endothelial cells. 
Preservation of the endothelial cells is of special importance, 
since injury to these cells can cause an aggravation of hepato-
cellular injury during reperfusion. Furthermore, the endothe-
lium is the first target of allogenic blood after transplantation, 
and injury here may cause an increase in the immunogenicity 
of the liver (16). 
It was found that lidoflazine increased the flush-out rate 
during harvesting, for all doses that also reduced the release of 
enzymes, except for the lowest dose (6.2±1.0, 6.8±0.4, 8.1±0.5 
[P<O.Ol), 7.9±0.S [(P<0.05], 9.1±1.2 [P<O.Ol), 6.S±0.4, and 
6.S±1.3 ml/min for the 0, 0.07S, 0.312, 1.25, 5, 20, and SO-mg 
lidoflazine/L groups, respectively; levels of significance com-
pared with the control group are within brackets). This effect 
is probably mediated by vasodilation. Theoretically, vasodila-
tion may be beneficial by contributing to a more rapid cooling 
of the organ and by improving the distribution of the preser-
vation solution within the parenchyma. However, in a small 
animal, such as the rat, both mechanisms are probably of little 
importance, since the duration of the harvesting procedure is 
short, and the small organ can quickly achieve a low tempera-
ture, once surrounded by ice. Also, in cold storage of rat organs 
with a relatively large surface area/volume ratio, simple diffu-
sion may be sufficient to supply a satisfactory distribution of 
the preservation solution. Thus, the present data suggest that 
the capacity of lidoflazine to improve liver preservation in this 
model is not caused mainly by dilatation of the vascular bed. 
However, for the preservation of larger organs such as the 
human liver, vasodilation may be an additional beneficial effect 
in a dose-related manner. 
The two highest doses of lidoflazine used here had no ame-
liorating effect on the release of liver enzymes, nor did they 
increase the flush-out rate. Nevertheless, lidoflazine appears to 
have a wide therapeutic window, as it was effective in a concen-
tration 10-7 M-lO-S M. It cannot be ruled out that an even 
lower dose than 10-7 could be effective, although this was never 
tested. 
The results from this investigation are in agreement with 
those of a previous study, in which lidoflazine was found to 
improve the preservation of rat kidneys (9). 
We conclude that lidoflazine improves the quality of liver 
preservation with UW solution in this in vitro model. However, 
further evaluation of this drug in a transplant model is required 
before the clinical usefulness can be determined. 
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FALSELY ELEVATED FK-506 LEVELS CAUSED BY SAMPLING THROUGH CENTRAL VENOUS CATHETERS 
FK-506 (Tacrolimus. ProGraf) is a potent immunosuppres-
sive agent that is currently being investigated at several centers 
in solid organ transplantation. Initial reports of efficacy have 
generated great interest among clinicians in the transplant 
community (1-4). Although immunosuppressive regimens with 
FK-506 appear to be effective, the drug has been associated 
with numerous adverse effects, most notably nephrotoxicity 
and neurotoxicity (4-8). The challenge remains to titrate the 
FK-506 dosage to its optimal immunosuppressive effect with 
minimal toxicity. This will require pharmacodynamic studies 
to define the therapeutic range for FK -506. For this to be 
accomplished, it is imperative that accurate drug concentration 
monitoring be carried out in conjunction with clinical evalua-
tions. A potential complication with this process has recently 
been discovered. 
The University of Nebraska Medical Center (UNMC) was 
involved in a multicenter randomized trial comparing the effi-
cacy of CsA versus FK-S06 in orthotopic liver transplantation. 
After transplantation. patients randomized to receive FK-S06 
were begun on a continuous infusion of FK-506 solution (0.02 
mg/m}) through a central venous catheter. The initial FK-506 
infusion was administered through an Edwards Swan-Ganz 
catheter (7.S French 110 em device manufactured by Baxter 
HealthCare, model #93A-8314) until patients were hemody-
namically stable, at which time the Swan-Ganz catheter was 
replaced by a triple-lumen central venous catheter (7 French 
30 em polyurethane device manufactured by Arrow product 
#AK147031. The infusion was continued for 72 hr or until the 
patient was able to take oral medication. 
A subset of patients in the primary FK-S06 trial gave in-
formed consent to participate in a concurrent pharmacokinetic 
protocol that consisted of multiple blood sampling over a 10-
day period. In this protocol. while FK -S06 was being infused 
through a Swan-Ganz catheter, serial blood samples were ob-
tained through indwelling peripheral arterial catheters. After 
the Swan-Ganz catheter was removed, blood samples were 
obtained as above or through an unused lumen of the triple-
lumen catheter. The sample technique was consistent through-
out the study; all blood samples were preceded by withdrawing 
and discarding 5 ml of blood (to purge the lumen of flush 
solution) and were followed by a 5- to 10-ml flush of 0.9% 
sterile sodium chloride solution. 
During the pharmacokinetic trial, it was noted that spu-
riously high whole blood and plasma concentrations, as meas-
ured by ELISA, were reported during the 12-hr period between 
discontinuation of i.v. FK-506 and the administration of the 
first oral dose. In multiple subjects, a 10- to 50-fold increase in 
the anticipated concentration was observed intermittently (9). 
An examination of procedures led us to suspect that the samples 
in question may have been drawn from the same catheter lumen 
previously used to infuse FK-S06 solution. We postulated that 
FK-506 or some component of the i.v. solution interacted with 
the triple lumen catheter, which led to sorption of FK-S06 in 
that lumen. 
To confirm our suspicions, simultaneous blood samples were 
obtained from the catheter lumen used to infuse FK -506, and 
from either a peripheral catheter or a lumen of the central 
venous catheter not used for FK-506 infusions in 2 subsequent 
patients enrolled in the pharmacokinetic trial. Samples were 
obtained at various times after termination of i.v. FK-506. 
Dramatic differences between the sampling sites were observed 
in whole blood and plasma concentrations in both patients 
(Table 1). The greatest degree of disparity between sampling 
sites occurred within the first hour after the end of i.v. FK-506 
infusion. Although the concentration ratio of the catheter lu-
men used to infuse FK-506 to the alternate lumen showed an 
obvious diminishing trend in both patients. an impressive dif-
ference (260%) persisted between sampling sites in patient 2. 
even though several days had elapsed. 
In a recent report, Taormina et a1. (JO) investigated the loss 
of FK-506 diluted in 5% dextrose or 0.9% sodium chloride in 
various containers and administration sets. Their results indi-
cate that over a 24-hr period. less than 10% of the initial FK-
506 concentration is lost when (1) FK-S06 is diluted in 5% 
dextrose and stored in glass bottles or polyolefin bags, or (2) 
FK-506 is diluted in 0.9% sodium chloride and stored in plastic 
syringes (Becton Dickinson & Co. brand) or polyolefin bags. 
However, greater than 10% of the initial FK-S06 concentration 
was lost with both solutions after only 6 hr in polyvinyl chloride 
bags. In the same study, a 2-hr infusion of FK-506 in 5% 
TABLE l. Whole blood and plasma FK-506 concentrations (ng/m\) as 
drawn from a catheter lumen used to administer FK-506 Isite B) and 
an uncontaminated alternate site (site A) 
Site A iuncontaml- Site B <FK-.506) nated) 
Time Ihr)G 
Plasma Whole blood Plasma Whole blood 
Ing/ml) Ing/ml) lng/mil lng/mil 
Patient 1 0.5 0.98b 30.0b 94.84 >240.0 
1.0 1.386 34.36 213.1 >240.0 
1.5 0.82 40.3 34.5 231.0 
Patient 2 1.0 3.09 29.7 231.0 >240.0 
1.5 2.66 32.5 183.0 >240.0 
2.0 2.58 28.4 35.6 198.0 
12.0 1.29 15.5 11.9 151.0 
114.0 4.86 32.5 11.5 102.0 
164.0 3.52 26.8 9.14 93.3 
a Time in elapsed hours from end of FK-506 infusion to sample 
collection. 
I> Indicates samples drawn through an arterial line: all other samples 
were obtained through a triple lumen catheter. 
